Condition: Castration-resistant Prostate Cancer · Sponsor: Radiopharm Theranostics, Ltd
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-KLK3 Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants with Castration-Resistant Prostate Cancer (CRPC).
This description comes directly from the study's public registry record.
Dimitris Voliotis, MD · 646-535-5017 · dv@radiopharmtheranostics.com
Always discuss trial participation with your own doctor first.
| Wollongong Hospital | Wollongong, New South Wales, Australia | Recruiting |
| Icon Cancer Centre Hollywood | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07259213